Supernus Pharmaceuticals Inc (SUPN)
R&D to Revenue
13.45%
Quarterly · Period ending:
SUPN R&D to Revenue
Latest reported13.45%period ending
Latest reported13.45%period ending
SUPN Quarterly R&D/Revenue (-145.07% → 13.45%)
Latest values, visible window
High-resolution chart · PNG
SUPN r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 13.4499% | |
| 18.9875% | |
| 13.1525% | |
| 15.2866% | |
| 13.3663% | |
| 17.9724% | |
| 16.4488% | |
| 16.5269% | |
| 15.555% | |
| 17.3554% | |
| 14.2088% | |
| 14.7225% | |
| 17.9835% | |
| 13.7952% | |
| 10.6223% | |
| 11.0255% | |
| 9.6353% | |
| 13.6644% | |
| 13.2524% | |
| 13.2382% | |
| 10.9355% | |
| 26.1815% | |
| 12.4954% | |
| 10.8544% | |
| 17.5548% | |
| 19.9387% | |
| 19.7041% | |
| 16.588% | |
| 16.209% | |
| 18.0102% | |
| 25.7396% | |
| 19.828% | |
| 20.131% | |
| 20.9092% | |
| 18.288% | |
| 16.1447% | |
| 14.2729% | |
| 16.6754% | |
| 21.246% | |
| 13.8497% | |
| 22.0325% | |
| 24.52% | |
| 22.1451% | |
| 23.6588% | |
| 19.6223% | |
| 13.0914% | |
| 18.7397% | |
| 8.8725% | |
| 15.7607% | |
| 49.3558% | |
| 52.274% | |
| 300.6364% | |
| 1,260.4982% | |
| 3,076.1905% | |
| 472.4771% | |
| 9,127.4725% | |
| 5,168.1319% | |
| 2,575.9615% | |
| -76.1808% | |
| 76,590.9091% | |
| 966.8% | |
| 0% | |
| -105.1388% | |
| 0% | |
| -145.0676% |